PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
Samsung Pharm continues to post operating losses in its core over-the-counter drug business, while the company's value hinges on the multi-indication development outcomes (PSP, Alzheimer's, pancreatic cancer) of GV1001, a drug candidate licensed from largest shareholder Gemvax & Kael.
2025 consolidated revenue was KRW 46.07 billion with an operating loss of KRW 18.07 billion that widened from the prior year, yet net income turned positive at KRW 11.55 billion.
On a quarterly basis, operating losses persisted every quarter while net income swung sharply into large surpluses in 2025Q2 (+KRW 63.57 billion) and 2026Q1 (+KRW 8.77 billion) driven by non-operating items.
In December 2025, the company secured rights to GV1001 for progressive supranuclear palsy (PSP) across four Asian countries from Gemvax, and applied for conditional domestic approval with MFDS in January 2026, which remains under review.
GV1001's global Phase 2 trial for Alzheimer's disease failed to meet its primary endpoint, while the domestic Phase 3 trial targets completing patient enrollment in 2026 and submitting a clinical study report in 2027.
Operating cash flow remained negative every year from 2022 to 2025, and the company continues to rely on external financing such as rights offerings and convertible bonds.
Founded in 1929, Samsung Pharm is one of Korea's longest-operating pharmaceutical companies, with its core business centered on over-the-counter drugs such as Gaseumsu, Sseulgidam, and Woohwang Cheongsim-hwan, along with health supplements and blood circulation boosters.
These traditional generic and OTC product lines form a stable revenue base and reportedly account for a significant portion of total sales.
The company's largest shareholder is Gemvax & Kael, which holds a 10.46% stake, while Samsung Pharm in turn holds roughly a 5% stake in Gemvax, forming a cross-shareholding structure.
Samsung Pharm's R&D portfolio is effectively centered on GV1001, a multi-mechanism peptide compound that Gemvax originally licensed from Norway in 2008.
Rights to develop and commercialize GV1001 in Korea were transferred to Samsung Pharm in stages: for pancreatic cancer in 2015 (conditional approval later revoked in 2020), for Alzheimer's disease in 2023, and for progressive supranuclear palsy (PSP) across Korea, Japan, India, and Indonesia in December 2025.
In January 2026, the company filed for conditional approval of GV1001 for PSP with Korea's Ministry of Food and Drug Safety (MFDS), a review that remains ongoing; if approved, the drug could be commercialized immediately subject to a confirmatory Phase 3 trial.
The Alzheimer's indication is in a domestic Phase 3 trial, targeting completion of patient enrollment within 2026 and submission of a clinical study report in 2027.
While pursuing three indications simultaneously for a single compound could amplify impact if successful, this strategy also carries the structural weakness of concentrated, undiversified pipeline risk.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩10.9B | -₩4.3B | −39.5% |
| 2025Q3 | ₩12B | -₩3.9B | −32.1% |
| 2025Q4 | ₩11.8B | -₩5.4B | −45.8% |
| 2026Q1 | ₩9B | -₩1.9B | −21.0% |
| 2026Q2 | ₩9.9B | -₩5.1B | −51.8% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩51.8B | -₩14B | -₩25.1B | −26.9% | −24.5% | 14.9% |
| 2023 | ₩52B | -₩18B | -₩24.8B | −34.7% | −32.0% | 20.5% |
| 2024 | ₩44.3B | -₩14.8B | -₩14.1B | −33.5% | −13.3% | 21.3% |
| 2025 | ₩46.1B | -₩18.1B | ₩11.5B | −39.2% | 9.5% | 38.3% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23
In 2025, consolidated revenue was KRW 46.07 billion, a modest increase from KRW 44.29 billion in 2024, but the operating loss widened to KRW 18.07 billion from KRW 14.83 billion, pushing the operating margin to -39.2%.
Net income attributable to owners, however, turned positive at KRW 11.55 billion, a reversal from large losses of KRW -14.09 billion in 2024 and KRW -24.81 billion in 2023 — a shift attributed not to core business improvement but to non-operating factors such as higher financial income.
Quarterly figures confirm this pattern: operating losses persisted without exception at KRW -4.30 billion in 2025Q2, -3.85 billion in 2025Q3, -5.42 billion in 2025Q4, -1.89 billion in 2026Q1, and -5.13 billion in 2026Q2.
In contrast, net income attributable to owners swung wildly, from +KRW 63.57 billion in 2025Q2 to -KRW 30.17 billion in 2025Q3, -KRW 59.10 billion in 2025Q4, +KRW 8.77 billion in 2026Q1, and -KRW 56.65 billion in 2026Q2, suggesting the dominant influence of non-operating items such as gains and losses on financial asset valuation.
Annual equity fell from KRW 102.59 billion in 2022 to KRW 77.58 billion in 2023, then rose again to KRW 105.86 billion in 2024 and KRW 121.04 billion in 2025 — a trend driven more by external capital raises such as rights offerings than by accumulated earnings.
The debt ratio also climbed from 14.9% in 2022 to 38.3% in 2025, somewhat weakening the balance sheet's cushion.
Operating cash flow remained negative for four consecutive years — KRW -1.91 billion in 2022, -27.66 billion in 2023, -17.30 billion in 2024, and -10.05 billion in 2025 — underscoring a persistent structural inability to generate cash from core operations.
Industry analysis has similarly noted Samsung Pharm as a case where an expanded operating loss in 2025 was offset by a swing to net profit driven by higher financial income.
Korea's listed pharmaceutical sector as a whole saw an improving profitability trend in 2025, with revenue and operating profit up 7.6% and 7.9% respectively, and net income surging 43.3%.
However, the OTC and health-supplement segment in which Samsung Pharm operates resembles a mature market with limited growth, unlike large prescription-drug, biosimilar, or licensing-driven biotech companies.
In contrast, companies with drug pipelines such as GV1001 tend to see valuations swing sharply around clinical and regulatory events, set against a backdrop where the global pharmaceutical and biotech industry is projected to grow at roughly 7% annually from 2024 to 2030, driven partly by the GLP-1 obesity-drug category.
Samsung Pharm's competitive position is twofold: in its traditional OTC business it competes against numerous small and mid-sized pharmaceutical firms, while in GV1001-related drug development it competes with other domestic developers of Alzheimer's and neurodegenerative disease treatments on clinical speed and data credibility.
Notably, PSP represents an area of unmet medical need with no globally approved treatment, positioning the company to potentially gain first-mover advantage in the domestic market if conditional approval is granted.
Conversely, the Alzheimer's treatment market is already intensely contested by major global pharmaceutical companies, and given that GV1001's global Phase 2 trial failed to meet its primary endpoint, the outcome of the domestic Phase 3 trial remains uncertain.
The nearest catalyst is the outcome of MFDS's conditional approval review for GV1001 in the PSP indication, filed in January 2026, with both the approval decision and its timing still unconfirmed.
If conditional approval is granted, domestic sales and supply could begin immediately, subject to a confirmatory Phase 3 trial — though the precedent of the pancreatic cancer indication, where conditional approval was revoked after the company missed the deadline to submit a clinical study report due to slow patient enrollment, shows a similar risk cannot be ruled out.
For the Alzheimer's Phase 3 trial, the company reduced the dosing arms and number of subjects through a 2024 IND amendment to shorten the trial period, and has set a target of completing patient enrollment within 2026 and submitting a final clinical study report (CSR) in 2027.
On the financing side, in March 2026 the company completed a KRW 48 billion rights offering with a general public subscription for forfeited shares, primarily to fund the Alzheimer's trial costs, which reportedly attracted subscription demand of nearly KRW 1.5 trillion.
However, given that operating cash flow has remained negative for four consecutive years, the need for additional external financing is likely to persist going forward.
The company also announced in March that it is pursuing ISO 37001 (anti-bribery management) and ISO 37301 (compliance management) certification, reflecting parallel efforts to improve governance amid recurring controversy over related-party transactions with its largest shareholder, Gemvax.
Samsung Pharm presents a challenging case for traditional earnings-based valuation, since operating losses persist every quarter while net income swings between large deficits and large surpluses depending on non-operating factors.
Market valuation appears to be driven less by current results than by expectations and uncertainty surrounding pipeline events such as the conditional approval decision for GV1001 in PSP and progress on the Alzheimer's Phase 3 trial.
From a price-to-book perspective, the gap between market value and net asset value is reportedly not especially wide, making it difficult to characterize the stock as trading at either a significant premium or discount to its asset base.
The company has not recently paid dividends, so valuation tends to hinge more on clinical and regulatory progress of the drug pipeline than on dividend appeal.
Because equity growth has been partly driven by external capital raises such as rights offerings, the quality of that capital expansion and the likelihood of further fundraising also warrant attention.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23
GV1001's PSP indication addresses an area of unmet medical need with no globally approved treatment, and conditional MFDS approval could position the company for first-mover advantage domestically.
Its 2024 designation as a rare disease drug in development may also work favorably for review speed, though the approval decision and timing remain unconfirmed.
Net income attributable to owners turned positive at KRW 11.55 billion in 2025, and equity has resumed an upward trend since 2022.
The March 2026 rights offering of KRW 48 billion attracted subscription demand of roughly KRW 1.5 trillion, demonstrating fundraising capacity, though this reflects non-operating factors and external financing rather than core business improvement.
Long-established OTC brands such as Gaseumsu, Sseulgidam, and Woohwang Cheongsim-hwan provide a stable revenue base. This traditional business generates a degree of steady cash inflow that acts as a buffer, independent of clinical failure risk in the drug pipeline.
Operating losses either widened or remained substantial every year from 2022 through 2025, and continued without exception on a quarterly basis. Operating cash flow has also been negative for four consecutive years, entrenching a structure in which the core business fails to generate cash.
GV1001's global Phase 2 trial for Alzheimer's disease failed to meet its primary endpoint. Since the company's R&D is concentrated on this single compound, disappointing results from the domestic Phase 3 trial could undermine a key pillar of the company's valuation case.
GV1001 licensing agreements with Gemvax have repeatedly drawn criticism for being executed shortly after failed capital raises, raising questions about intra-group fund circulation. Doubts persist over whether the cross-shareholding structure ensures fair pricing and independent validation of these deals.
GV1001 has a precedent of conditional approval being revoked in the pancreatic cancer indication after the company missed the clinical study report deadline due to slow patient enrollment. Similar delay risk cannot be ruled out for the PSP conditional approval review and Alzheimer's Phase 3 patient enrollment.
Gemvax and Samsung Pharm are related parties through cross-shareholding, and industry observers have repeatedly suggested that GV1001-related licensing agreements serve to circulate funds within the affiliated group.
Any similar related-party transactions in the future could raise concerns about conflicts with minority shareholder interests.
With operating cash flow negative for four consecutive years, the company has repeatedly relied on rights offerings and convertible bond issuances to fund GV1001 clinical trials and licensing costs. Continued reliance on external fundraising could heighten concerns over shareholder dilution.
Watch for MFDS's decision on the conditional approval review for GV1001 in the PSP indication; the outcome directly affects the commercialization timeline and subsequent Phase 3 obligations.
Check the (preliminary) Q3 2026 earnings disclosure to assess whether operating losses persist, the pace of cash depletion, and the need for further fundraising.
Confirm whether the target of completing patient enrollment for the GV1001 Alzheimer's Phase 3 trial by year-end 2026 is achieved, as this directly affects the 2027 clinical study report submission schedule.
Monitor for disclosures of additional rights offerings or convertible bond issuances. Given persistently negative operating cash flow, the frequency and scale of such fundraising warrant scrutiny for their impact on shareholder value.
Samsung Pharm's traditional OTC business provides a stable revenue base, but the company faces a structural problem of core operating losses that have persisted and widened for four consecutive years, while net income has swung between large deficits and large surpluses driven by non-operating factors.
The key variable for company value is the development progress of GV1001 — licensed from largest shareholder Gemvax — across its PSP, Alzheimer's, and pancreatic cancer indications, with the PSP conditional approval review and Alzheimer's Phase 3 patient enrollment being near-term events to watch.
However, optimism about pipeline success should be tempered by the precedent of conditional approval being revoked in the pancreatic cancer indication and the failure of the global Alzheimer's Phase 2 trial to meet its primary endpoint.
On the financing side, persistently negative operating cash flow alongside repeated rights offerings and convertible bond issuances warrant attention to potential further fundraising and shareholder dilution.
Market questions also persist regarding the fairness of licensing agreements conducted within the cross-shareholding relationship with the largest shareholder.
Before forming an investment view, it is important to balance a review of the PSP approval decision, Alzheimer's trial progress, and future fundraising disclosures.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.